Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
Enrolling by invitation · Phase 2 · NCT05794165
Conditions: Trauma Injury, Thromboembolism, Venous Thromboembolism
At a glance
- Research payments reported, 2025
- $1.9M
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 314
About the trial
- Sponsor
- Bryan Cotton (with Grifols Shared Services North America, Inc.)
- Tested
- Thrombate infusion (drug), Placebo (drug)
- Dates
- Started 2023-09-27; completion 2027-09
- Results posted
- Not yet
The purpose of this study is to determine if additional interventions will assist with decreasing the risk and/or severity of thromboembolism (clotting complications) in patients who have experienced a major traumatic event.
From ClinicalTrials.gov, last updated 2026-10-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Grifols Shared Services North America, Inc. reported $1.9M in research payments for this study in 2025 (11 payments).
Products named: Thrombate III
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael W. Cripps, MD General Surgery · Aurora, CO
- Jonathan P. Meizoso, MD, MSPH Trauma Surgery · Miami, FL
- Bryan Cotton, MD Trauma Surgery · Nashville, TN
- Bradley M. Dennis, MD Trauma Surgery · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of Texas Health Science Center at Houston $1.1M
- University of Colorado Hospital Authority, CO $433,118
- Vanderbilt University Medical Center, TN $204,315
- Jackson Health System, FL $203,280
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.